IP Library Granted Patent US 10,543,184
Granted Patent B2
US 10,543,184 · App. 14/543,403 · Granted Jan 28, 2020

Method to treat functional somatic syndromes with combination of aciclovir and celecoxib

Inventor: William L. Pridgen (Tuscaloosa, AL)
Assignee: INNOVATIVE MED CONCEPTS, LLC
A61K31/196A61K31/415A61K31/427A61K31/52A61K31/522A61K31/5415A61K31/5575A61K31/635A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,184
App. No.
14/543,403
Granted
Jan 28, 2020
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound aciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of aciclovir and celecoxib.

Claims (9)

1. A method to treat a subject susceptible to or afflicted with one or more functional somatic syndrome conditions comprising: fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, chronic pain, chronic headache, chronic neck pain, chronic back pain, chronic depression, chronic clinical anxiety disorder, post-traumatic stress disorder (PTSD), brain fog, cognitive dysfunction and chronic interstitial cystitis, the method comprising administering to the subject a therapeutically-effective combination of aciclovir and celecoxib, wherein the amount of aciclovir is administered in a total daily dose range from about 400 mg to about 1600 mg, and wherein the amount of celecoxib is administered in a total daily dose range from about 200 mg to about 800 mg, and wherein the combination administered produces no substantial adverse event.

2. The method of claim 1 , wherein the condition is selected from the group consisting of fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, chronic depression, chronic clinical anxiety disorder and chronic interstitial cystitis.

3. The method of claim 1 , wherein the condition is fibromyalgia.

4. The method of claim 1 , wherein the condition is chronic fatigue syndrome.

5. The method of claim 1 , wherein the condition is irritable bowel syndrome.

6. The method of claim 1 , wherein the condition is a combination of fibromyalgia, chronic fatigue syndrome and irritable bowel syndrome, coexistent in the subject.

7. The method of claim 1 , wherein the amount of aciclovir is administered in a total daily dose range from about 400 mg to about 1200 mg, and wherein the amount of celecoxib is administered in a total daily dose range from about 200 mg to about 500 mg.

8. The method of claim 1 , wherein the amount of aciclovir administered in a total daily dose is about 800 mg, and wherein the amount of celecoxib administered in a total daily dose is about 400 mg.

9. The method of claim 8 , wherein the condition is fibromyalgia.

Assignments (4)
CHANGE OF NAME Recorded Jan 16, 2025
From: VIRIOS THERAPEUTICS, INC.
To: DOGWOOD THERAPEUTICS, INC.
Reel/Frame 069934/0756 →
CHANGE OF NAME Recorded Jul 12, 2023
From: INNOVATIVE MED CONCEPTS, LLC
To: VIRIOS THERAPEUTICS, LLC
Reel/Frame 064265/0418 →
ENTITY CONVERSION Recorded Jul 12, 2023
From: VIRIOS THERAPEUTICS, LLC
To: VIRIOS THERAPEUTICS, INC.
Reel/Frame 064593/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2016
From: PRIDGEN, WILLIAM L., M.D.
To: INNOVATIVE MED CONCEPTS, LLC
Reel/Frame 038187/0213 →
Continuity (3)
Division 13761071 · Feb 6, 2013
Provisional Application 61595507 · Feb 6, 2012
Related Publication 20150072999A1 · Mar 12, 2015